Brief: Frequency Therapeutics Provides Business Updates And First Quarter 2023 Financial Results
Frequency Therapeutics Inc FREQ.O :
* FREQUENCY THERAPEUTICS PROVIDES BUSINESS UPDATES AND FIRST
QUARTER 2023 FINANCIAL RESULTS
* QTRLY LOSS PER SHARE $0.55
* FREQUENCY THERAPEUTICS-AS OF MARCH 31,CASH, CASH
EQUIVALENTS,
MARKETABLE SECURITIES OF $66.7 MILLION (EXCLUDING RESTRICTED
CASH), OR $55.0 MILLION NET OF DEBT
* Q1 EARNINGS PER SHARE VIEW $-0.42 -- REFINITIV IBES DATA
Source text for Eikon: ID:nBw7m9TMma
Further company coverage: FREQ.O
Recent news on Korro Bio
See all newsBrief: Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Korro Announces First Cohort Dosed In Phase 1/2 Clinical Trial (Anchor) For Krro-121
Brief: Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Korro Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Korro Bio, Inc. expected to post a loss of $1.43 a share - Earnings Preview